Bibliographies thématiques / Mucositi orali / Articles de revues

Articles de revues sur le sujet « Mucositi orali »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Mucositi orali.
Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Mucositi orali ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Simões, Cristiane Araújo, Jurema Freire Lisboa de Castro et Claudia Cazal. « Candida Oral como Fator Agravante da Mucosite Radioinduzida ». Revista Brasileira de Cancerologia 57, no 1 (31 mars 2011) : 23–29. http://dx.doi.org/10.32635/2176-9745.rbc.2011v57n1.681.

Texte intégral
Résumé :
Introdução: O tratamento antineoplásico provoca algumas sequelas indesejáveis no paciente com câncer de cabeça e pescoço. Muitas vezes, o surgimento de manifestações clínicas graves, como as mucosites, obriga a interrupção temporária do tratamento, diminuindo a qualidade de vida do paciente e aumentando os custos do seu internamento. É possível que a mucosite oral induzida pela irradiação e quimioterapia seja agravada por infecções fúngicas oportunistas que a torna mais resistente aos tratamentos convencionais. Objetivos: Este trabalho tem como objetivos identificar a presença de espécies de Candida e analisar a possibilidade deste fungo atuar como fator agravante da mucosite em pacientes portadores de câncer de cabeça e pescoço, os quais estejam sendo submetidos ao tratamento antineoplásico. Método: Os pacientes foram selecionados de modo consecutivo no Hospital do Câncer de Pernambuco no período compreendido entre outubro de 2008 a abril de 2009. A prevalência de Candida sp foi mensurada através da análise de raspados citológicos dos pacientes com mucosite oral. A presença do fungo foi correlacionada com o grau de severidade das lesões de mucosite. Resultados: Os resultados mostraram uma associação positiva entre a colonização fúngica e as lesões mais severas (graus III e IV). Conclusão: Os resultados apresentados podem contribuir para a resolução de mucosites não convencionais, as quais não respondem ao tratamento usual.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Florentino, Ana Carolina Andrade, Dhiancarlo Rocha Macedo, Edielly Fernanda David, Keller de Carvalho et Cizelene do Carmo Faleiros Veloso Guedes. « Tratamento da mucosite oral com laser de baixa potência : revisão sistemática de literatura ». Revista de Ciências Médicas 24, no 2 (9 mai 2016) : 85. http://dx.doi.org/10.24220/2318-0897v24n2a2959.

Texte intégral
Résumé :
Verificar qual o melhor protocolo de aplicação da laserterapia de baixa potência para prevenção e tratamento da mucosite oral químio e rádio induzida. Revisão sistemática de literatura sobre laserterapia na prevenção e tratamento da mucosite oral rádio e químio induzida. Foram utilizadas as indexações “mucositis”, “lowpower laser therapy”, na busca de estudos clínicos randomizados dos últimos 10 anos nas bases de dados de referência: PubMed, LILACS e Cochrane Library. A pesquisa resultou em 16 estudos clínicos randomizados sobre laserterapia de baixa potência, sendo consenso a aplicação 5 vezes por semana, com densidade de energia variada entre 1,3 e 6,0 J/cm². O presente estudo identificou que a laserterapia reduz o tempo de cicatrização e os graus de mucosite oral, apesar de ainda serem necessários mais estudos para definir o protocolo de atuação. Palavras-chave: Estomatite. Mucosite. Quimioterapia. Radioterapia. Terapia a laser de baixa intensidade.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Sá, Odara, Nilza Lopes, Maria Alves et Eliana Caran. « Effects of Glycine on Collagen, PDGF, and EGF Expression in Model of Oral Mucositis ». Nutrients 10, no 10 (12 octobre 2018) : 1485. http://dx.doi.org/10.3390/nu10101485.

Texte intégral
Résumé :
Oral mucositis is frequently a toxic effect of chemotherapeutic and/or radiotherapeutic treatment, resulting from complex multifaceted biological events involving DNA damage. The clinical manifestations have a negative impact on the life quality of cancer patients. Preventive measures and curative treatment of mucositis are still not well established. The glycine has anti-inflammatory, immunomodulatory, and cytoprotective actions, being a potential therapeutic in mucositis. The objective was to evaluate the effects of glycine on the expression of collagen and growth factors, platelet and epidermal in a hamster model oral mucositis. The mucositis was induced by the protocol of Sonis. There were 40 hamsters used, divided into two groups: Group I-control; Group II-supplemented with 5% intraperitoneal glycine, 2.0 mg/g diluted in hepes. Histopathological sections were used to perform the immune-histochemical method, the evaluation of collagen expression, and the growth factors: Epidermal growth factor (EGF) and platelet (PDGF). It was observed that the group supplemented with glycine experienced higher amounts of collagen expression and predominance type of collagen I. The glycine group presented lower immunoexpression of the growth factors, EGF and PDGF. The group supplemented with glycine showed a marked healing process of the oral mucosite, demonstrated by the predominance of collagen type I and reduction of growth factors, EGF and PDGF.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Muniz, Ana Bessa, Maria Aparecida Rodrigues de Holanda, Kleyton Nolasco de Abreu, Samuel Barbosa Macedo, Ellen Roberta Lima Bessa, Lady Daiane Pereira Leite, Mariana Raquel da Cruz Vegian, Rivaldave Rodrigues de Holanda Cavalcante et Rodrigo Asfury Rodrigues. « Mucosite oral em crianças com câncer : dificuldades de avaliação e de terapia efetiva ». Research, Society and Development 10, no 11 (5 septembre 2021) : e435101120018. http://dx.doi.org/10.33448/rsd-v10i11.20018.

Texte intégral
Résumé :
O câncer é um problema de saúde pública no mundo e, em crianças, a incidência de aumento é de cerca de 1% ao ano. Apesar da eficácia, a terapia antineoplásica provoca efeitos de significativa toxicidade, muitas vezes causando a hospitalização do paciente, dificuldades de continuação da oncoterapia ou não readequação do tratamento para a não progressão da doença. A mucosite oral é um dos efeitos deletérios mais comuns; causa dor, afeta a fala e a nutrição e torna o paciente suscetível à septicemia. Em crianças, a frequência da mucosite oral situa-se em torno de 65%. Suas manifestações são avaliadas por meio de escalas diferentes e tratadas com protocolos distintos. O objetivo deste trabalho é verificar, em uma revisão sistemática da literatura, o estado da arte da avaliação da mucosite oral em crianças sob tratamento oncológico. Estudos mostraram que a avaliação é fundamental para estabelecer as estratégias de tratamento, que protocolos e escalas utilizadas são inconsistentes e que inexiste um sistema viável e válido para pontuar a mucosite infantil causada por câncer, impedindo uma intervenção terapêutica mais efetiva. Concluiu-se que a Children’s International Mucositis Evaluation Scale vem sendo a escala de maior aceitabilidade e validade por seu critérios.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Schmidt, Eva, Nils H. Thoennissen, Annika Rudat, Ralf Bieker, Christoph Schliemann, Rolf M. Mesters, Michael Zühlsdorf, Carsten Müller-Tidow et Wolfgang E. Berdel. « Use of Palifermin for the Prevention of High-Dose Methotrexate-Induced Oral Mucositis. » Blood 110, no 11 (16 novembre 2007) : 4445. http://dx.doi.org/10.1182/blood.v110.11.4445.4445.

Texte intégral
Résumé :
Abstract Oral mucositis is a frequent problem in high-dose methotrexate (HD-MTX) based chemotherapy, impairing the patient’s quality of life, leading to higher rates of infections and delaying subsequent chemotherapy. Numerous substances have been used to prevent or treat oral mucositis, but none of them has proven clinical benefit. Palifermin, a recombinant human keratinocyte growth factor, can lead to a prevention of oral mucositis by different effects. Clinical activity of palifermin has been proven in a controlled randomized study with patients undergoing high-dose therapy with autologous stem cell rescue. The purpose of this report is to describe the effect of palifermin in patients treated within the GMALL-B-ALL 2002 protocol containing HD-MTX who developed a severe mucositis in cycles A1 or B1. Ten patients who were treated within this protocol developed a severe WHO grade III–IV oral mucositis in cycles A1 or B1. Before and after the subsequent similar or identical cycles A2 or B2 palifermin was given to reduce the risk of mucositis. Thus, patients serve as their own control for efficacy of palifermin. All ten patients developed a grade III–IV mucositis in cycles A1 or B1 without palifermin, whereas only 2/10 developed a grade III–IV mucositis in corresponding cycles A2 or B2 with palifermin (Mann-Whitney-Wilcoxon-test p < 0.05). Five patients were treated with a lower palifermin dose than recommended. Also these patients did not develop a higher grade mucositis. Only 4/10 patients showed infections in the cycles with palifermin compared to 10/10 patients without palifermin. The duration of mucositits in patients who aquired a higher-grade (III, IV) mucositis despite treatment with palifermin could be reduced from 12.9 days (median) without to 10.4 days with palifermin. In conclusion, palifermin can significantly reduce the incidence and severeness of oral mucositis and may influence clinical sequelae such as infection and quality of life.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Manjunathan, C., et Vijoykumar Singh. « An Impact of Coconut Oil Pulling on Oral Mucositis among Malignancy Patients ». Journal of Natural Remedies 22, no 1 (14 février 2022) : 43. http://dx.doi.org/10.18311/jnr/2022/27993.

Texte intégral
Résumé :
Acute or chronic oral complications may develop around 400,000 patients each year during chemotherapy. Oral mucositis happens in around 40% of patients who get malignancy chemotherapy<sup>1,2</sup>. Basically 75% of patients who get strong regimens develop oral mucositis. Treating oral mucositis with coconut oil has worked and battle all anti-viral, bacterial, and fungal properties<sup>3</sup>. The medium-chain unsaturated fats found in coconut oil which is immediately consumed into the body and thus the healing process is accelerated and it helps to enhance the body’s own immune system and hence assist it with battling all germs<sup>4</sup>. Coconut oil is a conventional treatment and is completely edible and natural<sup>5,6</sup>. It aims to evaluate the impact of coconut oil pulling on oral mucositis. A Quasi-experimental approach, convenient examining strategy, test size was 60 and the information was gathered through organized self-talk with questionnaires with standardized WHO Oral Mucositis Rating Scale. The Coconut oil pulling technique was administered to the experimental group. This group of people were administered with the coconut oil pulling technique and collected outcomes were analyzed statistically. The majority of samples had grade 3 rating in trial batch and in control batch larger part of them had grade 2 rating on severity of oral mucositis. The coconut oil pulling technique intervention was effective among cancer patients with oral mucositis of post-test results, the secured ‘t’ benefit was remarkable, p &lt;0.05 extent. The association between oral mucositis with their demographic variables are found was significant (p &lt;0.05). The technique tested was found to have significant outcomes for the experimental group. This group has less intensity of oral mucosistis as contrasted to the control group.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Ordonez Espinoza, Lili Ana, et Nilton Raúl Velásquez De la Cruz. « Manejo de la mucositis oral en pacientes que reciben quimioterapia, radioterapia o quimioradiación ». Cuidado y salud : Kawsayninchis 3, no 1 (25 mai 2018) : 303. http://dx.doi.org/10.31381/cuidado_y_salud.v3i1.1427.

Texte intégral
Résumé :
La mucositis oral es exclusivamente la inflamación y ulceración de la mucosa bucal, secundario a tratamiento anticancerígeno y ocurre en el 40-90% de pacientes. Ocasionando atrasos, suspensiones o reducciones en la intensidad del tratamiento; disminuye el control de la enfermedad y aumenta la morbimortalidad. Se trata de un artículo de actualización que revisa el manejo de la mucosistis oral secundaria a tratamiento quimio/radioterapeútico o ambos.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Soares, Gualberto De Abreu, Jurecir Da Silva Silva, Elaine Ferreira do Nascimento, Jéssica Pereira dos Santos et Jossuely Rocha Mendes. « EVIDÊNCIAS DA EFICÁCIA DA LASERTERAPIA DE BAIXA INTENSIDADE NA PREVENÇÃO E TRATAMENTO DA MUCOSITE ORAL ». Revista Univap 24, no 46 (17 décembre 2018) : 105. http://dx.doi.org/10.18066/revistaunivap.v24i46.356.

Texte intégral
Résumé :
Introdução: Dentre as formas de prevenção e controle da Mucosite Oral o uso dos Lasers de Baixa Intensidade destaca-se como eficiente. Objetivo: Avaliar as evidências científicas do uso da LBI na prevenção e tratamento da MO. Metodologia: Realizou-se uma pesquisa eletrônica na Biblioteca Virtual em Saúde – (www.bireme.br), onde foram selecionadas as publicações dos anos de 2003 a 2013, que possuíam como palavras chaves os termos; Mucosite, Lasers, Prevenção e controle, na língua portuguesa; e Mucositis, lasers, Prevention and control na língua inglesa. Foram selecionados 21 artigos pelos itens de inserção: (1) pesquisas escritas no idioma inglês ou portuguesa; (2) pesquisas de estudos experimentais; (3) pesquisas originais. Os itens de restrição foram: 1) trabalhos científicos que estivessem divulgados em outras formatações, como revisões e materiais educativos; 2) pesquisas que não contivessem seu resumo nas bases de dados selecionadas; 3) pesquisas de acesso restrito; 4) pesquisas com deficiência na descrição metodológica. Resultados: Encontrou-se 42% (n=9) dos artigos relatando do uso da laserterapia no tratamento da mucosite, 28% (n=6) na prevenção e 30% (n=7) na prevenção e tratamento. Discussão: O laser de Arseneto de Gálio e Alumínio, com comprimento de onda de 660nm, potência de 30mW e densidade de energia 2 J/cm2, aplicado de forma pontual é o mais eficiente. Conclusão: A LBI é eficiente na prevenção e tratamento da Mucosite Oral. Entretanto, não existe uma padronização de protocolos de uso e muito menos trabalhos que busquem resolver essa particularidade.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Spezzia, S. « Mucosite Oral ». Journal of Oral Investigations 4, no 1 (30 juin 2015) : 14–18. http://dx.doi.org/10.18256/2238-510x/j.oralinvestigations.v4n1p14-18.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Singh, Vibha, et AkhileshKumar Singh. « Oral mucositis ». National Journal of Maxillofacial Surgery 11, no 2 (2020) : 159. http://dx.doi.org/10.4103/njms.njms_10_20.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
11

Sonis, Stephen T. « Oral mucositis ». Anti-Cancer Drugs 22, no 7 (août 2011) : 607–12. http://dx.doi.org/10.1097/cad.0b013e3283462086.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
12

Scully, C., S. Sonis et PD Diz. « Oral mucositis ». Oral Diseases 12, no 3 (mai 2006) : 229–41. http://dx.doi.org/10.1111/j.1601-0825.2006.01258.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
13

Davison, Deborah. « Oral Mucositis ». Clinical Journal of Oncology Nursing 10, no 2 (1 avril 2006) : 283–84. http://dx.doi.org/10.1188/06.cjon.283-284.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Raber-Durlacher, Judith E., Sharon Elad et Andrei Barasch. « Oral mucositis ». Oral Oncology 46, no 6 (juin 2010) : 452–56. http://dx.doi.org/10.1016/j.oraloncology.2010.03.012.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
15

Lalla, Rajesh V., et Douglas E. Peterson. « Oral mucositis ». Dental Clinics of North America 49, no 1 (janvier 2005) : 167–84. http://dx.doi.org/10.1016/j.cden.2004.07.009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Da Conceição, Taís Correia, Ana Carla Barletta Sanches, Tila Fortuna Costa Freire, Gabriela Botelho Martins, Marcelo Victor Coelho Marques et Juliana Borges de Lima Dantas. « Acute Oral Manifestations in Patients Submitted to Radiotherapy in the Head and Neck Region : Literature Narrative Review ». Journal of Health Sciences 23, no 2 (21 juin 2021) : 92–98. http://dx.doi.org/10.17921/2447-8938.2021v23n2p92-98.

Texte intégral
Résumé :
AbstractThe use of ionizing radiation, affects not only malignant cells but also healthy tissues, and promotes several side acute or late effects in the oral cavity. Among the acute effects, oral mucositis, xerostomia, hyposalivation, dysgeusia and dysphagia present a prominent role. The present study aims to conduct a narrative literature review on radiotherapy in the head and neck region as a therapeutic modality for cancer in this region and the main acute oral manifestations and their respective treatments. This was an exploratory literature review, through the database of Scielo, Pubmed, Medline and institutional websites using the crossing of the descriptors in English and Portuguese “head and neck neoplasms”, “radiotherapy”, “xerostomia”, “dysgeusia” and “dysphagia”. According to the established criteria, a total of 46 articles and 2 institutional websites were selected from the databases, and one book was added for presenting relevance on this theme. The results demonstrate that oral mucositis is the most prevalent acute effect and has a direct impact on patient’s quality of life, but there is no gold standard treatment. Dysphagia, xerostomia, hyposalivation and dysgeusia are common manifestations in irradiated patients, and present several therapeutic modalities. Given the importance of side effects of radiotherapy in head and neck region, further studies are needed to widely disseminate acute oral manifestations in irradiated patients. Keywords: Oral Mucositis. Head and Neck Neoplasms. Radiotherapy. Xerostomia. ResumoA utilização de radiação ionizante, no câncer de cabeça e pescoço, afeta não somente células malignas, mas também tecidos sadios, o que promove diversos efeitos colaterais em cavidade oral, classificados em agudos ou tardios. Dentre os efeitos agudos, a mucosite oral, xerostomia, hipossalivação, disgeusia e disfagia apresentam papel de destaque. O presente trabalho visou realizar uma revisão narrativa de literatura sobre a radioterapia em região de cabeça e pescoço como modalidade terapêutica para o câncer nesta região e as principais manifestações orais agudas decorrentes da radiação ionizante e seus respectivos tratamentos. Tratou-se de revisão de literatura do tipo exploratória, através das bases de dados da Scielo, Pubmed, Medline e sites institucionais utilizando o cruzamento dos descritores em inglês e português “neoplasias de cabeça e pescoço”, “radioterapia”, “mucosite oral”, “xerostomia”, “disgeusia” e “disfagia”. De acordo com os critérios estabelecidos, um total de 46 artigos e 2 sites institucionais foram selecionados nas bases de dados, e 1 livro foi acrescentado por apresentar relevância sobre a temática em questão. Os resultados demonstram que a mucosite oral é o efeito agudo mais prevalente e apesar de ter impacto direto na qualidade de vida, não há tratamento considerado padrão ouro para esta condição. A disfagia, xerostomia, hipossalivação e disgeusia são manifestações comuns em pacientes irradiados, e apresentam diversas modalidades terapêuticas que podem ser empregadas. Dada à importância dos efeitos colaterais da radioterapia de cabeça e pescoço, torna-se necessária a realização de mais estudos afim de divulgar amplamente as manifestações orais agudas em pacientes irradiados. Palavras-chave: Mucosite Oral. Neoplasias de Cabeça e Pescoço. Radioterapia. Xerostomia
Styles APA, Harvard, Vancouver, ISO, etc.
17

De Mello Andrade, Julia, et Giovanna Castilho Davatz. « Protocolos de laserterapia para prevenção e tratamento da mucosite oral induzida por radioterapia ou quimioterapia ». Revista Feridas, no 52 (15 février 2022) : 1877–85. http://dx.doi.org/10.36489/feridas.2022v10i52p1877-1885.

Texte intégral
Résumé :
Objetivo: Apresentar uma revisão bibliográfica sobre protocolos de prevenção e tratamento com laserterapia para os casos de Mucosite Oral. Métodos: A partir da string: “oral mucositis AND (photobiomodulation OR low level laser therapy) AND (protocol OR treatment OR effectiveness OR efficacy)” realizou-se busca de artigos científicos nas bases de dados PubMed e Scielo. Resultados: A literatura apontou que a laserterapia pode ser utilizada tanto para prevenção quanto para a cura da Mucosite Oral, em tratamentos de 4 a 14 dias. O comprimento de onda utilizado é de 630 nm a 970 nm, do vermelho ao infravermelho, com incidência nos locais selecionados variando de 10 segundos a aproximadamente 1 minuto. Dentre os locais de aplicação estão lábios superior e inferior, língua, palato mole e duro, assoalho bucal, bochecha, arcos palatoglosso e palatofaríngico e úvula, além de lesões e regiões avermelhadas. Foi considerado tratamento seguro, bem tolerado, reduzindo a dor, a frequência e o grau das lesões. Também melhora a função salivar e deglutição. Conclusão: Há diferentes protocolos de laserterapia para Mucosite Oral. Cabe ao aplicador a partir dos dados da literatura escolher o número de dias de tratamento, comprimento de onda, tempo e pontos de irradiação. Com a intervenção há redução da frequência e grau das lesões, além de diminuição de até 75% do uso de analgésicos e melhora da deglutição em até 100% dos casos.
Styles APA, Harvard, Vancouver, ISO, etc.
18

Morais, Jaylinne Ribeiro, Thiago Rêgo Vanderley, Rômulo Diego Monte Soares, Augusto Everton Dias Castro, Sarah Nilkece Mesquita Araújo et Maria Helena Barros Araújo Luz. « Characterization of the patient with chemotherapy-induced oral mucositis / Caracterização do paciente com mucosite oral induzida por quimioterapia / Caracterización de la paciente con mucositis oral inducida por quimioterapia ». Revista de Enfermagem da UFPI 4, no 1 (17 juin 2015) : 26. http://dx.doi.org/10.26694/reufpi.v4i1.1739.

Texte intégral
Résumé :
Objectives: To characterize cancer patients with oral mucositis treated at a private health facility. Methodology: An exploratory study with descriptive quantitative approach developed in 87 patients in a private practice oncology in Teresina, PI, from August 2011 to January 2012. Results: Findings indicated the prevalence of oral mucositis in males and in the age groups 40-59 years and more than 60. The most common cancer diagnoses were gastrointestinal tract and breast cancer, the treatments focused on chemoradiation, determining predominantly grades I and II of oral mucositis. Overall, mucositis had low discontinuation of cancer treatment and nursing procedures were mainly observed when patients had mucositis grade I. Conclusion: Patients are mostly female, age 40-59 years, with an education 11 or more years. Have an income 2-4 minimum wages and the most frequent types of cancers were the gastrointestinal tract and breast cancer, respectively. Descriptors: Stomatitis. Oncology. Chemotherapy. Nursing
Styles APA, Harvard, Vancouver, ISO, etc.
19

Markiewicz, Miroslaw, Dzierzak Mietla Monika, Patrycja Zielinska, Tomasz Kruzel, Tomasz Czerw et Slawomira Kyrcz-Krzemien. « Caphosol Mouth Rinse Diminishes Oral Mucositis In Allo-HSCT Recipients. » Blood 116, no 21 (19 novembre 2010) : 3498. http://dx.doi.org/10.1182/blood.v116.21.3498.3498.

Texte intégral
Résumé :
Abstract Abstract 3498 Introduction: Oral mucositis is a complication of conditioning treatment that produces pain and morbidity in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. The rationale of this study was to evaluate the efficacy of a calcium phosphate mouth rinse (Caphosol) vs standard regimen in 40 adult patients undergoing allo-HSCT. Patients and Methods: 40 patients treated with allo-HSCT (31 from unrelated donors, 9 from siblings) performed in Hematology and BMT center in Katowice in 2009 were randomized and stratified by the conditioning regimen (busulfan-, treosulfan- or TBI- based), type of transplant (unrelated or related) and age into two equal groups. Treatment group received Caphosol washes 4 times daily from first day of conditioning until reaching ANC 0.2 G/l. Control group received standard topical mouth care with salvia, antibacterial and antifungal solutions. During the trial patients subjectively assessed level of pain in mouth and in pharynx using 0–10 scale and swallowing problems using 0–5 scale. Mucositis was judged by experienced physician. Nonparametric Mann-Whitney U-tests were used for statistical analysis. Results: Average oral toxicity in WHO scale in Caphosol vs control group was 0.9 vs 1.8 (p=0.02), duration of mucositis was 3.2 vs 7.1 days (p=0.02). Total parenteral nutrition (TPN) due to mucosits was required in Caphosol vs control group in 0 vs 6 pts, average duration of TPN was 0 vs 1.9 days (p=0.009). Analgetics were required, respectively, in 3 vs 9 pts and analgesy lasted for 1.1 vs 3.4 days (p=0.047). Average subjective peak pain in mouth was 0.85 vs 1.75 (p=0.005) and in pharynx 1.95 vs 2.2 (NS) in Caphosol vs control group, average pain intensity was lower in Caphosol group throughout the whole period of mucositis. Intensity of swallowing problems tended to be lower in Caphosol group (NS). Acute GVHD was observed in 7 vs 9 pts in Caphosol vs control group and its average degree was 0.5 vs 0.9 (NS). Conclusions: Caphosol mouth rinse in the allo-HSCT recipients is associated with decrease of oral toxicity, lower peak pain due to mucositis and its shorter duration. In consequence, comfort of life is improved and the incidence of acute GVHD is reduced, as well as the requirement of TPN and analgetics. Disclosures: No relevant conflicts of interest to declare.
Styles APA, Harvard, Vancouver, ISO, etc.
20

Schmitt, M. « F21 Oral mucositis ». Critical Reviews in Oncology/Hematology 72, no 1 (octobre 2009) : S12. http://dx.doi.org/10.1016/s1040-8428(09)70023-x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Gibson, John, David Wray et Jeremy Bagg. « Oral staphylococcal mucositis ». Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 89, no 2 (février 2000) : 171–76. http://dx.doi.org/10.1067/moe.2000.101810.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

Parulekar, W., R. Mackenzie, G. Bjarnason et R. C. K. Jordan. « Scoring oral mucositis ». Oral Oncology 34, no 1 (janvier 1998) : 63–71. http://dx.doi.org/10.1016/s1368-8375(97)00065-1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Bajracharya, Barsha, Subrata Bhattacharyya et Pratibha Poudel. « Evaluation of oral mucositis in oral cancer patients undergoing radiotherapy ». Journal of Chitwan Medical College 8, no 2 (30 juin 2018) : 6–9. http://dx.doi.org/10.3126/jcmc.v8i2.23730.

Texte intégral
Résumé :
Introduction: The present study was conducted to evaluate oral mucositis in oral cancer patients receiving head and neck radiotherapy. Methods: Sixty oral cancer patients who had received at least 40 grays of radiation were included in the study. Mucositis was scored by oroscopy using WHO scale. Grades of mucositis were then compared with total dose of radiation received by the patients. Results: The cases were receiving the mean cumulative dose of standard radiation therapy of 2Gy per fraction, 5 fractions per week. All the patients developed oral mucositis. The majority had grade I mucositis, followed by grade III, II and IV. The grade of mucositis was directly proportional to the dose of radiation exposure. Conclusion: Oral mucositis occurs among all the patients undergoing head and neck radiotherapy and grade of mucositis is proportional to the dose of radiation exposure.
Styles APA, Harvard, Vancouver, ISO, etc.
24

ÇAKMAK, Seher, et Nesrin NURAL. « Evaluation of Oral Mucositis in Cancer Patients ». Turkiye Klinikleri Journal of Nursing Sciences 10, no 4 (2018) : 319–29. http://dx.doi.org/10.5336/nurses.2018-60361.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Hunter, Ann, Prem Mahendra, Keith Wilson, Paul Fields, Gordon Cook, Andrew Peniket, Charles Crawley et al. « A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantion (PBSCT). » Blood 108, no 11 (16 novembre 2006) : 45. http://dx.doi.org/10.1182/blood.v108.11.45.45.

Texte intégral
Résumé :
Abstract Mucositis is a serious complication of PBSCT. ATL-104 is a recombinant protein, the L-form of phytohaemagglutinin, a potent mitogenic for epithelial cells of the GI tract, resistant to acid and protease degradation. A prospective, pilot study was conducted to assess the effect of ATL-104 on mucositis in patients receiving high dose melphalan (66%) or BEAM (34%) before an autologous PBSCT. Each dose consisted of 15mL of solution containing 50, 100, or 150mg ATL-104 or placebo. For 3 days prior to chemotherapy and for 3 days following transplantation patients swilled the solution in the mouth for 15–30 seconds and then swallowed. Assessments were made for 28 days following dosing or until discharge, for pain, ulceration and the other factors which contribute to the WHO (World Health Organisation) or WCCNR (Western Consortium Cancer Research Nurses) mucositis scales. The first part of the study used a dose ascending design, commencing with 50 mg ATL-104, with patients randomised 3:1, active:placebo. A safety review was performed after 8 patients at each dose. After completion of the 150 mg cohort, a randomised parallel arm design with all doses and placebo was used (1:1:1:1). In total, 63 patients (46 M, 17 F) were treated; 15/16 patients in each group; 54 received all six doses and were fully assessed. ATL-104 at all doses produced a consistent reduction in duration of all grades of oral mucositis, compared to placebo (no statistical significance testing planned). For WHO grades 3–4, the reduction was 4.4, 4.2 and 3.4 days for ATL-104 50mg, 100mg and 150mg respectively, a fall of between 51%–64%, compared with placebo. There were also reductions in the duration of mucositis on the WCCNR scale. There was a reduction in the duration of ulceration scored 1–4, of 2.7, 0.8 and 2.4 days for ATL-104 50mg, 100mg and 150mg respectively, a fall of between 15–43% compared to placebo. No clear effect of ATL-104 on the incidence of mucositis or patients perception of pain was apparent. ATL-104 was well tolerated at all doses. Conclusion: ATL-104 warrants further investigation in larger, randomised, clinical trials. Placebo ATL-104 50 mg ATL104 100mg ATL-104 150 mg Incidence WHO Grades 3–4 Mucositis (%) 50 46 31 67 Duration WHO Grades 3–4 Mucositis (days/SD) 6.7 (1.5) 2.3 (1.5) 2.5 (1.7) 3.3 (1.7) Incidence WHO Grades 2–4 Mucositis (%) 71 62 77 67 Duration WHO Grades 2–4 Mucositis (days/SD) 6.9 (4.0) 4.0 (2.3) 4.9 (3.6) 4.8 (4.5) Incidence WCCNR Grades 2–3 Mucositis (%) 93 92 85 93 Duration WCCNR Grades 2–3 Mucosits (days/SD) 11.6 (5.3) 8.2 (4.7) 8.1 (4.0) 7.8 (2.5) Incidence of Mouth Ulcers Scored 1–4 (%) 71 62 62 68 Duration Mouth Ulcers Scored 1–4 (days/SD) 6.3 (4.2) 3.6 (2.5) 5.5 (3.8) 3.9 (2.1) Incidence Pain/Soreness 1–10 (%) 77 53 77 83 Duration Pain/Soreness 1–10 (days/SD) 7.4 (4.4) 7.0 (3.9) 5.3 (3.4) 6.4 (3.4)
Styles APA, Harvard, Vancouver, ISO, etc.
26

Sadasivan, Raj. « Chemotherapy-induced Oral Mucositis ». Oncology & ; Hematology Review (US) 06 (2010) : 13. http://dx.doi.org/10.17925/ohr.2010.06.0.13.

Texte intégral
Résumé :
Oral mucositis is one of the most common side effects cancer patients experience when undergoing chemotherapy. However, it is frequently under-reported and leads to high morbidity and complication rates. Advances in molecular biology have provided greater insight into the pathophysiology of this condition. Although there are no current treatments that completely resolve this painful condition, encouraging research developments indicate that a new, over-the-counter pH-balanced salt solution, reBalanceCa, shows promise.
Styles APA, Harvard, Vancouver, ISO, etc.
27

da Vasconcelos, Mota, Serpa Sampaio, França de et Jurema de. « Management of oral mucositis ». Archive of Oncology 20, no 3-4 (2012) : 57–61. http://dx.doi.org/10.2298/aoo1204057d.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
28

Satheesh Kumar, PS, Anita Balan, Arun Sankar et Tinky Bose. « Radiation induced oral mucositis ». Indian Journal of Palliative Care 15, no 2 (2009) : 95. http://dx.doi.org/10.4103/0973-1075.58452.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Knox, Jennifer J., Anitasha L. V. Puodziunas et Ronald Feld. « Chemotherapy-Induced Oral Mucositis ». Drugs & ; Aging 17, no 4 (octobre 2000) : 257–67. http://dx.doi.org/10.2165/00002512-200017040-00002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

N/A. « Oral Mucositis and Chemotherapy ». Biological Therapies in Dentistry 17, no 01 (2001) : 001. http://dx.doi.org/10.2310/7040.2001.9481.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Lee, Hye-Jin, Jeong-Seung Kwon, Young-Chan Choi et Hyung Joon Ahn. « Methotrexate-induced Oral Mucositis ». Journal of Oral Medicine and Pain 40, no 2 (30 juin 2015) : 82–87. http://dx.doi.org/10.14476/jomp.2015.40.2.82.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Moe, Peter Johan. « Methotrexate and Oral Mucositis ». Pediatric Hematology and Oncology 13, no 4 (janvier 1996) : 313–14. http://dx.doi.org/10.3109/08880019609030836.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Hutchinson, Lisa. « Washing out oral mucositis ». Nature Reviews Clinical Oncology 12, no 11 (22 septembre 2015) : 624. http://dx.doi.org/10.1038/nrclinonc.2015.158.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

Vahanwala, Sonal, et Sandeep Pagare. « Strategies in Management of Oral Mucositis ». International Journal of Head and Neck Surgery 1, no 2 (2010) : 61–67. http://dx.doi.org/10.5005/jp-journals-10001-1012.

Texte intégral
Résumé :
Abstract Oral mucositis is a clinically important and sometimes dose-limiting complication of Cancer Therapy. Mucositis lesions are painful, affect nutrition, quality of life and often hampers continuity of the treatment modality. The pathogenesis of oral mucositis is multifactorial and complex. This is a review paper which discusses various aspects a clinician should know in management of mucositis.
Styles APA, Harvard, Vancouver, ISO, etc.
35

KOBYA BULUT, Hacer. « Oral Mucositis Results in Pediatrics Cancer Patients : Review ». Turkiye Klinikleri Journal of Nursing 8, no 4 (2016) : 343–47. http://dx.doi.org/10.5336/nurses.2016-51854.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

Chen, Joey, Jamie Seabrook, Adrienne Fulford et Irina Rajakumar. « Icing oral mucositis : Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant ». Journal of Oncology Pharmacy Practice 23, no 2 (9 juillet 2016) : 116–20. http://dx.doi.org/10.1177/1078155215620920.

Texte intégral
Résumé :
Background Up to 70% of patients receiving hematopoietic stem cell transplant develop oral mucositis as a side effect of high-dose melphalan conditioning chemotherapy. Oral cryotherapy has been documented to be potentially effective in reducing oral mucositis. The aim of this study was to examine the effectiveness of the cryotherapy protocol implemented within the hematopoietic stem cell transplant program. Methods A retrospective chart review was conducted of adult multiple myeloma patients who received high-dose melphalan conditioning therapy for autologous hematopoietic stem cell transplant. Primary endpoints were incidence and severity of oral mucositis. Secondary endpoints included duration of oral mucositis, duration of hospital stay, parenteral narcotics use and total parenteral nutrition use. Results One hundred and forty patients were included in the study, 70 patients in both no cryotherapy and cryotherapy groups. Both oral mucositis incidence and severity were found to be significantly lower in the cryotherapy group. Fifty (71.4%) experienced mucositis post cryotherapy compared to 67 (95.7%) in the no cryotherapy group (p < 0.001). The median oral mucositis severity, assessed using the WHO oral toxicity scale from grade 0–4, experienced in the no group was 2.5 vs. 2 in the cryotherapy group (p = 0.03). Oral mucositis duration and use of parenteral narcotics were also significantly reduced. Duration of hospital stay and use of parenteral nutrition were similar between the two groups. Conclusion The cryotherapy protocol resulted in a significantly lower incidence and severity of oral mucositis. These results provide evidence for the continued use of oral cryotherapy, an inexpensive and generally well-tolerated practice.
Styles APA, Harvard, Vancouver, ISO, etc.
37

Chattopadhyay, Subrata, Aramita Saha, Mohammad Azam, Anindya Mukherjee et Prabir Kumar Sur. « Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis : A prospective randomized study ». South Asian Journal of Cancer 03, no 01 (janvier 2014) : 008–12. http://dx.doi.org/10.4103/2278-330x.126501.

Texte intégral
Résumé :
Abstract Background: Oral mucositis is the most frequently occurring painful and dose-limiting side-effect of radiation of the head and neck region. Few studies demonstrated that oral glutamine suspension may significantly reduce the duration and severity of objective oral mucositis during radiotherapy. Materials and Methods: A randomized, prospective single institutional case control study was performed between April 2012 and November 2012 comparing the influence of oral glutamine on radiation induced mucositis in head and neck malignancy patients. Seventy biopsy proven patients with head and neck cancer receiving primary or adjuvant radiation therapy were randomized to receive either oral glutamine suspension daily 2h before radiation in the study arm (10 g in 1000 ml of water) (n = 35) or nothing before radiation; control arm (n = 35). Results and Analysis: Total 32 patients (91.43%) in the glutamine arm and total 34 patients (97.15%) developed mucositis. Grade 3 mucositis (14.29%) and grade 4 mucositis (2.86%) in the study arm (who received oral glutamine) were significantly less (P = 0.02 and P = 0.04, respectively) in the glutamine arm. The mean duration of grade 3 or worse mucositis (grade 3 and grade 4) was significantly less (6.6 days vs. 9.2 days) in study arm with P < 0.001. Mean time of onset of mucositis was significantly delayed in patients who took glutamine in comparison to control arm with P < 0.001. Conclusion: Glutamine delays oral mucositis in the head neck cancer patients. Moreover, it reduces the frequency and duration of grade 3 and grade 4 mucositis.
Styles APA, Harvard, Vancouver, ISO, etc.
38

Brown, Timothy J., et Arjun Gupta. « Management of Cancer Therapy–Associated Oral Mucositis ». JCO Oncology Practice 16, no 3 (mars 2020) : 103–9. http://dx.doi.org/10.1200/jop.19.00652.

Texte intégral
Résumé :
Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled pain, superinfection or systemic infection, bleeding, and dehydration, and severe mucositis can lead to interruptions or de-escalation in anticancer treatment, resulting in worse oncologic outcomes. This article provides an evidence-based summary to guide practicing oncologists in the assessment, prevention, and management of mucositis induced by chemotherapy, radiotherapy, and targeted therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
39

Erika, Kadek Ayu, Mulhaeriah Mulhaeriah, Upik Anderiani Miskad, Eli Zuraida et Harun Achmad. « Effectiveness of Oral Cryotherapy for Oral Mucositis on Cancer Patient Undergoing Cancer Therapy : A Systematic Review ». Open Access Macedonian Journal of Medical Sciences 9, F (30 novembre 2021) : 650–59. http://dx.doi.org/10.3889/oamjms.2021.7712.

Texte intégral
Résumé :
BACKGROUND: Oral mucositis is one of the complications in patients undergoing cancer therapy. Oral cryotherapy (OC) is an intervention to reduce the severity of oral mucositis. AIM: To identify, analyze, and evaluate articles regarding the effectiveness of cryotherapy for oral mucositis in cancer patients undergoing cancer therapy. METHODS: We performed searching on seven databases (PubMed, CENTRAL, Wiley, CANCERLIT, Science Direct, EBSCO, and SpringerLink). The investigation focused on English-language articles, intervention, or observational study reporting on the effectiveness of OC against oral mucositis in patients undergoing chemotherapy, and published between October 2015 and October 2020. RESULTS: Eleven articles met the eligibility criteria for inclusion consisting of 5 RCTs, 3 Quasi-Experiment studies, 2 Cohort studies, and one pre-experimental study. The majority of the studies show that OC is an effective intervention to reduce the degree and severity of oral mucositis in patients undergoing cancer therapy (Hematopoietic Stem Cell Transplantation and chemotherapy). CONCLUSION: OC is practical, low-cost, and relatively safe and can be an alternative therapy in reducing oral mucositis as a side effect of cancer therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
40

Hentilä, Jessica, Noora Laakamaa, Timo Sorsa, Jukka Meurman, Hanna Välimaa, Sakari Nikinmaa, Esko Kankuri, Tuomas Tauriainen et Tommi Pätilä. « Dual-Light Photodynamic Therapy Effectively Eliminates Streptococcus Oralis Biofilms ». Journal of Pharmacy & ; Pharmaceutical Sciences 24 (22 septembre 2021) : 484–87. http://dx.doi.org/10.18433/jpps32084.

Texte intégral
Résumé :
Purpose: During cancer treatment, oral mucositis due to radiotherapy or chemotherapy often leads to disruption of the oral mucosa, enabling microbes to invade bloodstream. Viridans streptococcal species are part of the healthy oral microbiota but can be frequently isolated from the blood of neutropenic patients. We have previously shown the antibacterial efficacy of dual-light, the combination of antibacterial blue light (aBL) and indocyanine green photodynamic therapy (aPDT). Methods: Here, we investigated the dual-light antibacterial action against four-day Streptococcus oralis biofilm. In addition, while keeping the total radiant exposure constant at 100J/cm2, we investigated the effect of changing the different relative light energies of aBL and aPDT to the antibacterial potential. Results: The dual-light had a significant antibacterial effect in all the tested combinations. Conclusion: Dual-light can be used as an effective disinfectant against S. oralis biofilm.
Styles APA, Harvard, Vancouver, ISO, etc.
41

LOWRY, FRAN. « Oral Hygiene Important for Preventing Oral Mucositis ». Family Practice News 38, no 9 (mai 2008) : 51. http://dx.doi.org/10.1016/s0300-7073(08)70617-0.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

Sonis, Stephen T. « Mucositis : The impact, biology and therapeutic opportunities of oral mucositis ». Oral Oncology 45, no 12 (décembre 2009) : 1015–20. http://dx.doi.org/10.1016/j.oraloncology.2009.08.006.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Castagnola, M., E. Scarano, G. C. Passali, I. Messana, T. Cabras, F. Iavarone, G. Di Cintio, A. Fiorita, E. De Corso et G. Paludetti. « Salivary biomarkers and proteomics : future diagnostic and clinical utilities ». Acta Otorhinolaryngologica Italica 37, no 2 (avril 2017) : 94–101. http://dx.doi.org/10.14639/0392-100x-1598.

Texte intégral
Résumé :
Lo studio della proteomica salivare, test economico e non invasivo, rappresenta una fonte di numerose informazioni, ed è utile per la diagnosi di svariate malattie. Da quando siamo entrati nell’era della tecnologia genomica e delle scienze “omiche”, la raccolta di campioni salivari è aumentata esponenzialmente. Recenti piattaforme proteomiche hanno analizzato il proteoma salivare umano, caratterizzando circa 3000 peptidi e proteine, espressi in maniera differente: più del 90% in peso deriva dalla secrezione delle tre ghiandole salivari maggiori, mentre la restante parte proviene dalle ghiandole salivari minori, dal fluido crevicolare gengivale, da essudati mucosi e dalla microflora orale. L’obiettivo principale dell’analisi proteomica è discriminare tra condizioni fisiologiche e patologiche. Ad oggi, tuttavia, non esiste un preciso protocollo che permetta di analizzare l’intero proteoma salivare, pertanto sono state realizzate svariate strategie. Innanzitutto, è possibile distinguere due tipologie di piattaforme proteomiche: l’approccio “top-down” prevede l’analisi delle proteine sotto esame come entità intatte; nell’approccio “bottom-up” la caratterizzazione della proteina avviene mediante lo studio dei peptidi ottenuti dopo digestione enzimatica (con tripsina tipicamente). A causa di questa eterogeneità, per una stessa patologia sono stati proposti differenti biomarkers. Il proteoma salivare è stato caratterizzato in numerose malattie: carcinoma squamoso e leucoplachie orali, malattia del trapianto contro l’ospite (GVHD) cronica, sindrome di Sjögren e altri disordini autoimmuni come la sindrome SAPHO (sinovite, acne, pustolosi, iperostosi e osteite), schizofrenia e disordine bipolare, malattie genetiche come la sindrome di Down o la malattia di Wilson. In conclusione, i risultati delle ricerche riportate in questa review suggeriscono che nel prossimo futuro la saliva diverrà un fluido di indubbia rilevanza diagnostica utile per fini clinici, sia diagnostici, sia prognostici.
Styles APA, Harvard, Vancouver, ISO, etc.
44

Froum, Stuart, Eduardo González de la Torre et Paul Rosen. « Peri-implant Mucositis ». International Journal of Periodontics & ; Restorative Dentistry 39, no 2 (février 2019) : e46-e57. http://dx.doi.org/10.11607/prd.3976.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
45

Gupta, Tejpal, Rahul Krishnatry, Ankita A. Nachankar et Jai Prakash Agarwal. « Oral Radiation Mucositis : A Short Review ». International Journal of Head and Neck Surgery 2, no 1 (2011) : 37–43. http://dx.doi.org/10.5005/jp-journals-10001-1045.

Texte intégral
Résumé :
ABSTRACT Oral radiation mucositis is one of the debilitating and dose-limiting acute toxicity during (chemo) radiation or for HNC having a major impact on the patient daily functioning, well-being and quality of life. The unplanned interruption of treatment secondary to mucositis may compromise the treatment and the outcomes if not adequately addressed. Recently, the integrated pathophysiological mechanism of radiation injury has been proposed, aiding development of certain targeted therapies for the prevention and treatment of oral mucositis. Although there are currently no approved agents or strategies that can reliably prevent or treat oral mucositis, there are several agents are under investigation and development. This is an exciting juncture in the development of drugs and drug delivery agents for radiation oral mucositis. This review is to have a peep into currently available options at present to optimally know when these agents can be used and what should be the direction of future research to maximize the therapeutic benefit.
Styles APA, Harvard, Vancouver, ISO, etc.
46

Bruce, Susan D., et Annette Quinn. « The Pain of Oral Mucositis ». Oncology & ; Hematology Review (US) 00, no 01 (2007) : 86. http://dx.doi.org/10.17925/ohr.2007.00.01.86.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
47

Verdi, Christopher J. « Cancer Therapy and Oral Mucositis ». Drug Safety 9, no 3 (septembre 1993) : 185–95. http://dx.doi.org/10.2165/00002018-199309030-00004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
48

Tovani-Palone, MarcosRoberto, et Sridhar Premkumar. « Oral mucositis : Treatment and prevention ». European Journal of General Dentistry 9, no 1 (2020) : 53. http://dx.doi.org/10.4103/ejgd.ejgd_168_19.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
49

Peterson, Douglas E. « Research advances in oral mucositis ». Current Opinion in Oncology 11, no 4 (juillet 1999) : 261. http://dx.doi.org/10.1097/00001622-199907000-00005.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
50

Sunavala-Dossabhoy, G., F. Abreo, PS Timiri Shanmugam et G. Caldito. « Histopathologic grading of oral mucositis ». Oral Diseases 21, no 3 (30 septembre 2014) : 355–60. http://dx.doi.org/10.1111/odi.12287.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Mucositi orali » pour d’autres types de sources :
Thèses
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie